MTH1 - The story
We proudly present a completely novel way of treating cancer, which has been published in Nature.
The new concept is that cancer cells are killed by their own high level of intrinsic oxidative stress, not present in normal cells. We target the MTH1 protein required to prevent oxidative stress in cancer to become DNA damage. Normal cells have low level of oxidative stress and don’t need the MTH1 protein. See how the concept works!
The Helleday Foundation
The Helleday Foundation is raising funds to bring the MTH1 concept to cancer patients.
By donating to the Helleday Foundation you help them support the MTH1 project in order to bring treatment to patiens faster.
Visit www.helledayfoundation.org and donate today! Let's fight cancer together.
New treatment approved!
PARP inhibitors have been recently approved for the treatment of ovarian cancers in women with BRCA mutations.
The Helleday Laboratory discovered this novel way of killing cancer in 2005 and after successful clinical trials, Lynparza (olaparib) has been granted market authorization.
150,000 women in the European Union suffer from ovarian cancer and many of these patients will benefit from this new therapy.
A successful case
Marie had her third relapse of ovarian cancer and contacted Thomas Helleday after she had heard about the PARP inhibitor treatment. She was entered into the trial and the cancer was eradicated.
"Naturally, I am extremely happy and impressed by your work. There are of course not enough words to describe how grateful I am, both for myself and for my children and family's sake. It gives real hope of breaking the chain of cancer in the family. I hope that it will soon appear on the market so that more can be helped by it."